Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPI-1831
- Development stage
- Preclinical
- Lead developer
- Beta Pharma
- Modality
- Small Molecules
01
Overview
BPI-1831 is a small molecule inhibitor of the c-Met (hepatocyte growth factor receptor) tyrosine kinase, currently in development by Beta Pharma Technologies. It is primarily targeted toward the treatment of non-small cell lung cancer (NSCLC), where c-Met dysregulation—such as MET amplification or exon 14 skipping mutations—acts as a significant driver of malignancy and resistance to EGFR-targeted therapies. By selectively inhibiting the c-Met signaling pathway, BPI-1831 aims to suppress tumor cell proliferation, survival, and epithelial-mesenchymal transition (EMT). As of the latest pipeline updates, the compound was in the IND-enabling stage of development.
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on BPI-1831.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPI-1831.